Keygene Selects 454's Sequencing Technology to Enable Large-Scale SNP Discovery
News Jan 13, 2006
454 Life Sciences Corporation, subsidiary of CuraGen Corporation, has announced that its Genome Sequencer 20 system has been selected and purchased by Keygene N.V. to enable its proprietary Complexity Reduction of Polymorphic Sequences (CRoPS™) technology.
The Genome Sequencer 20 system was developed by 454 Life Sciences and is distributed by Roche Applied Science.
Keygene and 454 Life Sciences have also entered into a collaboration to develop other proprietary applications in the field of plant genetics.
"Keygene is a leading service provider in the genetic analysis of plants, animals and micro-organisms," said Chris McLeod, President and CEO of 454 Life Sciences.
"We are pleased that they have selected the Genome Sequencer 20 to enable the CRoPS technology, and we look forward to collaborating with Keygene to continue to advance plant genetics."
Keygene developed the CRoPS technology to enable large-scale single nucleotide polymorphism discovery and detection in higher eukaryotic organisms, including plants with very large and complex genomes.
The CRoPS method, which Keygene will present to the scientific community at the Plant & Animal Genome Conference in San Diego on January 17-19, 2006, works through combining AFLP® mediated DNA complexity reduction methods with the powerful high-throughput sequencing technology developed by 454.
"We selected and purchased the Genome Sequencer 20 system because our research showed that it was the only platform currently available with throughput sufficient for the needs of our CRoPS technology," stated Arjen van Tunen, Keygene's CEO.
"This collaboration with 454 Life Sciences enables Keygene to create better solutions for our research partners and customers by continuing to increase the efficiency of genotyping in plants."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.